SACI-IO HR+:SG联合或不联合帕博利珠单抗治疗HR阳性/HER2阴性转移性乳腺癌的随机II期试验
该随机II期研究比较戈沙妥珠单抗(SG)联合或不联合帕博利珠单抗治疗内分泌治疗经治、化疗0-1线的HR阳性/HER2阴性转移性乳腺癌,主要终点无进展生存期(PFS)在总体人群未显著改善(8.4 vs 6.7个月,P=0.12),但PD-L1阳性亚组PFS和OS有数值上获益趋势。
要点
- SG联合帕博利珠单抗未显著改善总体人群PFS(8.4 vs 6.7个月,P=0.12)。
- PD-L1阳性亚组联合组PFS和OS有数值获益趋势,需更大样本验证。
- TROP2表达、TILs等标志物与结局无关,ctDNA高比例和PIK3CA突变与更差PFS相关。
核心结论
- 在未按PD-L1选择的HR阳性/HER2阴性转移性乳腺癌中,SG联合帕博利珠单抗未显著改善结局。
- PD-L1阳性人群中联合组PFS和OS有数值获益趋势,值得进一步研究。
研究设计与样本
- 随机II期研究,104例经内分泌治疗且针对转移性疾病化疗0-1线(未用过TOP1i)的HR阳性/HER2阴性转移性乳腺癌患者,1:1随机接受SG联合帕博利珠单抗或SG单药。
- 主要终点为PFS,关键次要终点包括PD-L1阳性人群PFS、OS、ORR和毒性。
主要发现
- 中位随访15.5个月,联合组与单药组中位PFS分别为8.4个月和6.7个月(HR 0.76,95%CI 0.48-1.19,P=0.12)。
- 中位OS分别为20.0个月和18.0个月(P=0.18),ORR分别为28.8%和19.2%(P=0.36)。
- PD-L1阳性人群(44%;39/88有组织)中位PFS分别为11.1个月和5.6个月(HR 0.51,95%CI 0.24-1.12,P=0.09),中位OS分别为18.5个月和12.5个月(HR 0.59,95%CI 0.18-1.98,P=0.39)。
- 常见≥2级不良事件包括中性粒细胞减少、脱发、乏力、贫血、恶心、白细胞减少和腹泻。
- TROP2表达(免疫组化、免疫荧光或血浆表观基因组分析)及肿瘤浸润淋巴细胞与结局无关;循环肿瘤DNA高比例和PIK3CA突变与更差PFS相关。
临床怎么用
- 当前证据不支持在未选择PD-L1的HR阳性/HER2阴性转移性乳腺癌中常规联合帕博利珠单抗与SG。
- PD-L1阳性患者可考虑参加进一步随机试验探索联合治疗。
局限性
- II期研究样本量有限(104例),PD-L1阳性亚组分析为探索性,统计效能不足。
- 随访时间中位15.5个月,OS数据尚未成熟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sacituzumab govitecan (SG), a TROP2-directed topoisomerase I-inhibitor (TOP1i) antibody-drug conjugate, is approved for chemorefractory hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). To evaluate if pembrolizumab (programmed cell death protein 1 inhibitor) enhances the activity of SG, we conducted a randomized phase II study comparing SG with or without pembrolizumab in HR-positive/HER2-negative MBC. MATERIALS AND METHODS: Patients with HR-positive/HER2-negative MBC pretreated with endocrine therapy and 0-1 chemotherapy regimens for MBC (no prior TOP1i) were randomly assigned 1:1 to receive SG plus pembrolizumab or SG. Primary endpoint was progression-free survival (PFS). Key secondary endpoints included PFS in the programmed death-ligand 1 (PD-L1)-positive population (pharmDx 22C3 combined positive score ≥1), overall survival (OS), objective response rate (ORR), and toxicity. Baseline tumor tissue and plasma samples were collected for correlative analyses. RESULTS: Between March 2021 and January 2024, 104 patients started treatment; 47% (49) had not received chemotherapy for MBC. At 15.5-month median follow-up, SG plus pembrolizumab did not significantly improve PFS compared with SG [8.4 versus 6.7 months; hazard ratio (HzR) 0.76, 95% confidence interval (CI) 0.48-1.19, P = 0.12]. Median OS was 20.0 versus 18.0 months (P = 0.18); ORR was 28.8% versus 19.2% (P = 0.36). In the PD-L1-positive population (44%; 39/88 with tissue), median PFS (11.1 versus 5.6 months; HzR 0.51, 95% CI 0.24-1.12, P = 0.09) and OS (18.5 versus 12.5 months; HzR 0.59, 95% CI 0.18-1.98, P = 0.39) numerically increased with the combination. Most frequent grade ≥2 adverse events were neutropenia, alopecia, fatigue, anemia, nausea, leukopenia, and diarrhea. Neither TROP2 expression by immunohistochemistry, immunofluorescence, or plasma epigenome-based analysis, or tumor-infiltrating lymphocytes were associated with outcomes. Higher circulating tumor DNA fraction and PIK3CA mutations were associated with worse PFS. Plasma epigenome-pathway analysis suggested that high cell cycle or epithelial-mesenchymal transition activation may confer sensitivity or resistance to SG, respectively. CONCLUSION: Addition of pembrolizumab to SG did not significantly improve outcomes in HR-positive/HER2-negative MBC unselected by PD-L1. In the PD-L1-positive population, the trend in PFS and OS favoring SG plus pembrolizumab warrants further investigation in larger randomized trials.
引用
- Garrido-Castro AC, Kim SE, Li T, et al. SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer. Ann Oncol. 2026. PMID: 42323161. doi:10.1016/j.annonc.2026.06.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。